|
Biochemical Pharmacology Discussion Group
The Biochemical Pharmacology Discussion Group represents a diverse group of scientists from pharmaceutical and biotechnology companies and university and medical research centers interested in biochemistry, molecular biology, biomedical research, and related areas. The group brings together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development. The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Chapter.
Full list of 2012 BPDG symposia (PDF, 20 KB)
Upcoming Events
Tuesday, September 25, 2012 | 8:30 AM - 6:00 PM
Organizers: Zdenek Berger (Pfizer), Mercedes Beyna (Pfizer), Warren Hirst (Pfizer), Jennifer Henry (The New York Academy of Sciences)
Speakers: Zdenek Berger (Pfizer), Ana Maria Cuervo (Albert Einstein College of Medicine), Daniel J. Klionsky (University of Michigan), Beth Levine (University of Texas Southwestern Medical Center), Ralph A. Nixon (Nathan Kline Institute), Eileen P. White (Rutgers University), Richard J. Youle (NINDS), Zhenyu Yue (Mount Sinai School of Medicine)
Autophagy is a route for degradation of aggregated cellular proteins and dysfunctional organelles. This symposium reviews molecular mechanisms of impairment, and discusses drug discovery strategies for modulating autophagy for therapeutic benefits.
Tuesday, October 23, 2012 | 8:30 AM - 5:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Heather Shih (Pfizer External Research Solutions), Mohammad Tabrizi (Merck Research Laboratory), Jennifer Henry, PhD, The New York Academy of Sciences
Speakers: Anthony Coyle (Pfizer), Peter Kiener (Zyngenia), Serge Muyldermans (Vrijie Universiteit Brussel, Belgium), Carl Nathan (Weill Cornell Medical College), Mohammad Tabrizi (Merck Research Laboratory), K. Dane Wittrup (Massachusetts Institute of Technology), Anna Wu (University of California, Los Angeles)
There are many monoclonal antibody therapeutics on the market, and myriad development candidates. We review the application of cutting-edge technologies to the development of next-generation antibody therapeutics and address translational challenges.
Steering Committee
|
Bristol-Myers Squibb
Cochair
|
Boehringer Ingelheim
|
|
Pfizer
|
Mount Sinai Medical School
|
|
Merck
|
Ahmad Fawzi, PhD
GPCR BioSciences Inc.
|
|
Boehringer Ingelheim
|
Weill Cornell Medical College
Cochair
|
|
Cell Therapy Group
|
Bristol-Myers Squibb
Secretary
|
|
Boehringer Ingelheim
|
Forest Research Institute
|
|
Novartis Pharmaceuticals
|
Boehringer Ingelheim
|
Charles Lunn, PhD
|
Covance Biomarker Center of Excellence
|
Martha Matteo, PhD
|
Broad Institute
|
|
Drew University
|
Pat Rose, PhD
|
|
New York Medical College
|
Eisai, Inc.
|
|
AstraZeneca Pharmaceuticals LP
|
June Sonnenberg-Reines, PhD
|
|
Lundbeck Research USA
|
Edward Tamer, PhD
|
|
Novartis Institutes for BioMedical Research
|
Intra-Cellular Therapies Inc.
|
|
MLV
|
Sponsors
The Biochemical Pharmacology Discussion Group is proudly supported by:
Mission Partner support for the Frontiers of Science program provided by:
Get more information about how you can sponsor a discussion group.
|
|